Medicare Part D market

Brimonidine Tartrate

CY2024

Medicare Part D · CY2024 · as published by CMS

Part D Brimonidine Tartrate Medication

ScopeMedicare Part D prescription drug plans, Medicare Advantage drug plans included, CY2024. A claim is one dispensed fill, refills included. It is not a prescription written and not a patient count.

Sold as

	share of claims	prescribers, this brand row
Brimonidine Tartrate	90.4%	90,478
Alphagan P	9.5%	24,546
Mirvaso	0.0%	265

Each prescriber count belongs to one brand row and is never summed.

In CMS's filePublished in every year, CY2020–CY2024, as Brimonidine Tartrate.

Part D drug cost Explore — see the Part D drug cost for this → Gross amount paid at the pharmacy, before manufacturer rebates.

As published by CMS · Medicare Part D Prescribers by Geography and Drug, and by Provider and Drug, CY2024

Market overview

Market size 2,691,855 claims for Brimonidine Tartrate in CY2024, and 4,885,592 30-day fills, as CMS publishes them.
Growth Up 6.2% year over year; +11.6% over five years (2020 → 2024).
Prescribers CMS reports prescribers for each of the 3 brand rows, on the Brands and generics tab. Counts are per brand and are never summed.
Where it is prescribed The three largest state markets are California, Florida, and New York — together 30.1% of claims.

Data year CY2024 CY2023 CY2022 CY2021 CY2020

How to read these figures

Claims count dispensed fills, refills included; a claim is not a prescription written and not a patient count. CMS withholds any prescriber with 10 or fewer claims for a brand row, so a prescriber missing from a list is not confirmed absent and every disclosed count is a floor. Totals and prescriber rows come from two separate CMS files that are not built to reconcile, so a prescriber list never adds up to a published total. Shares are computed only against the totals CMS publishes for the place. Prescriber counts belong to one brand row and are never summed across brands, because one clinician can write several brands. All figures are calendar years.

This medication's Overview — its five-year claims trend, and how many state markets publish a total for it — is part of Explore.

See the Part D drug cost

An Explore subscription, $249 a seat a year, opens this medication's Overview, and shows what Medicare Part D spends on it.

It comes with 25 credits a seat a year for Deep Dives, which open the rest.

Subscribe to Explore →